BCL2 and acute myeloid leukemia: Finally, combinatorial treatments involving BCL-2 inhibitors (e.g., navitoclax) together with FLT3 inhibitors (e.g., gilteritinib) have demonstrated synergistic anti-leukemic effects in AML cells carrying both NUP98::NSD1 fusions and FLT3-ITD mutations, suggesting that such drug combinations may improve therapeutic outcomes for this subgroup of patients.